ORACLE: A clonal-expression biomarker predicts stage I NSCLC outcome
Jarushka Naidoo shared on X:
“ORACLE: A clonal-expression biomarker predicts stage I NSCLC outcome
23 transcript assay, association with OS
summarizes clonal evolution
predicts benefit adj plt-chemo, via chromosomal instability
Go TRACERx”
Authors: Dhruva Biswas, Yun-Hsin Liu, Javier Herrero, Yin Wu, David A. Moore, Takahiro Karasaki, Kristiana Grigoriadis, Wei-Ting Lu, Selvaraju Veeriah, Cristina Naceur-Lombardelli, Neil Magno, Sophia Ward, Alexander M. Frankell, Mark S. Hill, Emma Colliver, Sophie de Carné Trécesson, Philip East, Aman Malhi, Daniel M. Snell, Olga O’Neill, Daniel Leonce, Johanna Mattsson, Amanda Lindberg, Patrick Micke, Judit Moldvay, Zsolt Megyesfalvi, Balazs Dome, János Fillinger, Jerome Nicod, Julian Downward, Zoltan Szallasi, TRACERx Consortium, Allan Hackshaw, Mariam Jamal-Hanjani, Nnennaya Kanu, Nicolai J. Birkbak, Charles Swanton.
Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland.
She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.
She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023